Featured Trial
Our review committee has reviewed this trial and it meets our criteria for going above and beyond. Learn more about featured trials.
Clinical Trial Goal
To find out if belumosudil is safe and works well to treat chronic GVHD in children and adults who are ethnically diverse
You may be able to join this trial if you:
- Are 12 years old or older
- Have chronic GVHD
- Identify with one of the following ethnicities:
- American Indian or Alaska Native
- Black or African American
- Native Hawaiian or Other Pacific Islander
- Have not been treated for chronic GVHD with the drugs ibrutinib or ruxolitinib. Your doctor can tell you this
- Do not have post-transplant lymphoproliferative disease (PTLD)
- Your cancer has not come back (relapsed)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Belumosudil is drug that blocks ROCK2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Belumosudil – A pill that you take by mouth 1-2 times each day
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have blood tests or biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 4 years.
The Food and Drug Administration (FDA) has approved belumosudil to treat chronic GVHD. Studying it specifically in ethnically diverse patients is new and unproven.
Contacts
Trial Transparency email recommended (Toll free for US & Canada), 800-633-1610, Contact-US@sanofi.com
Locations
Sponsors
lead: Kadmon, a Sanofi Company
